Lumeon is driving real change in today’s complex healthcare system. With our industry-leading Lumeon Care Pathway Management (CPM) platform and suite of solutions, we enable healthcare organizations to automate systems and processes, bringing together the full potential of their organization to deliver high performance, team-centered healthcare.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

INDUSTRIAL IMPACT

NOVALIQ SUBMITS NEW DRUG APPLICATION SEEKING APPROVAL FOR FIRST-OF-A-KIND DRY EYE DISEASE TREATMENT CYCLASOL®

Novaliq GmbH | August 10, 2022

news image

Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, announced the submission of a New Drug Application to the U.S. Food and Drug Administration seeking approval for CyclASol® a proposed novel treatment for the signs and symptoms of dry eye disease. CyclASol® has demonstrated in two pivotal studies fast onset of therapeutic effect in the indication, clinical meaningful improveme...

Read More

MEDICAL

NIKANG THERAPEUTICS COMPLETES $200 MILLION SERIES C FINANCING TO ADVANCE HIGHLY DIFFERENTIATED SMALL MOLECULES ADDRESSING DIFFICULT-TO-DRUG TARGETS

NiKang Therapeutics | May 31, 2021

news image

NiKang Therapeutics Inc., a clinical-stage biotech company focused on developing innovative small molecule oncology medicines to assist patients with unmet medical needs; today announced the completion of an oversubscribed $200 million Series C financing led by Cormorant Asset Management, HBM Healthcare Investments, and Octagon Capital Advisors with participation from a premier syndicate of funds, including new investors EcoR1 Capital, Perceptive Advisors, Wellington Management, Ally Bridge Grou...

Read More

INDUSTRIAL IMPACT

SECOND GENOME ANNOUNCES BAYER EXERCISED OPTION FOLLOWING COMPLETION OF MULTI-YEAR COLLABORATION

Second Genome | March 03, 2022

news image

Second Genome, a biotechnology company that leverages its proprietary platform to discover and develop precision therapies and biomarkers, announced today it has completed its multi-year collaboration with Bayer to discover proteins for potential development of next-generation insect-control products. During the collaboration, Second Genome generated and explored environmental metagenomes that include genomic information from bacteria that are yet to be identified and cultured. Read More

CELL AND GENE THERAPY

ALNYLAM ANNOUNCES NEW MANAGEMENT APPOINTMENTS

Alnylam Pharmaceuticals | September 22, 2022

news image

Alnylam Pharmaceuticals, Inc. the leading RNAi therapeutics company, announced the appointment of two new members to the management team – Piyush Sharma as Chief Ethics & Compliance Officer and Evan Lippman in the newly created role of Chief Corporate Development and Strategy Officer. Both executives will report to Chief Executive Officer, Yvonne Greenstreet. “Attracting and retaining top talent is one of my top priorities, and I’m thril...

Read More
news image

INDUSTRIAL IMPACT

NOVALIQ SUBMITS NEW DRUG APPLICATION SEEKING APPROVAL FOR FIRST-OF-A-KIND DRY EYE DISEASE TREATMENT CYCLASOL®

Novaliq GmbH | August 10, 2022

Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, announced the submission of a New Drug Application to the U.S. Food and Drug Administration seeking approval for CyclASol® a proposed novel treatment for the signs and symptoms of dry eye disease. CyclASol® has demonstrated in two pivotal studies fast onset of therapeutic effect in the indication, clinical meaningful improveme...

Read More
news image

MEDICAL

NIKANG THERAPEUTICS COMPLETES $200 MILLION SERIES C FINANCING TO ADVANCE HIGHLY DIFFERENTIATED SMALL MOLECULES ADDRESSING DIFFICULT-TO-DRUG TARGETS

NiKang Therapeutics | May 31, 2021

NiKang Therapeutics Inc., a clinical-stage biotech company focused on developing innovative small molecule oncology medicines to assist patients with unmet medical needs; today announced the completion of an oversubscribed $200 million Series C financing led by Cormorant Asset Management, HBM Healthcare Investments, and Octagon Capital Advisors with participation from a premier syndicate of funds, including new investors EcoR1 Capital, Perceptive Advisors, Wellington Management, Ally Bridge Grou...

Read More
news image

INDUSTRIAL IMPACT

SECOND GENOME ANNOUNCES BAYER EXERCISED OPTION FOLLOWING COMPLETION OF MULTI-YEAR COLLABORATION

Second Genome | March 03, 2022

Second Genome, a biotechnology company that leverages its proprietary platform to discover and develop precision therapies and biomarkers, announced today it has completed its multi-year collaboration with Bayer to discover proteins for potential development of next-generation insect-control products. During the collaboration, Second Genome generated and explored environmental metagenomes that include genomic information from bacteria that are yet to be identified and cultured. Read More

news image

CELL AND GENE THERAPY

ALNYLAM ANNOUNCES NEW MANAGEMENT APPOINTMENTS

Alnylam Pharmaceuticals | September 22, 2022

Alnylam Pharmaceuticals, Inc. the leading RNAi therapeutics company, announced the appointment of two new members to the management team – Piyush Sharma as Chief Ethics & Compliance Officer and Evan Lippman in the newly created role of Chief Corporate Development and Strategy Officer. Both executives will report to Chief Executive Officer, Yvonne Greenstreet. “Attracting and retaining top talent is one of my top priorities, and I’m thril...

Read More